PROSAP1 - Proline-Rich Synaptic-Associated Protein 1 (SHANK2)
<style>
.infobox {
float: right;
width: 320px;
padding: 12px;
background: #f8f9fa;
border: 1px solid #ddd;
margin-left: 20px;
font-size: 0.9em;
}
.infobox th {
background: #e9ecef;
padding: 6px;
text-align: left;
}
.infobox td {
padding: 4px 6px;
}
</style>
<div class="infobox">
| Property | Value |
|----------|-------|
| Symbol | PROSAP1 (SHANK2) |
| Name | Proline-Rich Synaptic-Associated Protein 1 |
| Chromosome | 11q13.2 |
| NCBI Gene ID | 22989 |
| OMIM | 606344 |
| Ensembl | ENSG00000046192 |
| UniProt | Q9UHB6 |
| Protein Length | 2,070 amino acids |
| Molecular Weight | ~225 kDa |
</div>
Introduction
PROSAP1, also known as SHANK2 (SH3 and Multiple Ankyrin Repeat Domains 2), is a critical postsynaptic scaffold protein that orchestrates the organization of the postsynaptic density (PSD) in excitatory synapses. Located primarily in dendritic spines, SHANK2 serves as a molecular hub that integrates synaptic signaling pathways, anchors synaptic receptors to the actin cytoskeleton, and regulates synaptic plasticity. [@shank2_structure_2019]
...
PROSAP1 - Proline-Rich Synaptic-Associated Protein 1 (SHANK2)
<style>
.infobox {
float: right;
width: 320px;
padding: 12px;
background: #f8f9fa;
border: 1px solid #ddd;
margin-left: 20px;
font-size: 0.9em;
}
.infobox th {
background: #e9ecef;
padding: 6px;
text-align: left;
}
.infobox td {
padding: 4px 6px;
}
</style>
<div class="infobox">
| Property | Value |
|----------|-------|
| Symbol | PROSAP1 (SHANK2) |
| Name | Proline-Rich Synaptic-Associated Protein 1 |
| Chromosome | 11q13.2 |
| NCBI Gene ID | 22989 |
| OMIM | 606344 |
| Ensembl | ENSG00000046192 |
| UniProt | Q9UHB6 |
| Protein Length | 2,070 amino acids |
| Molecular Weight | ~225 kDa |
</div>
Introduction
PROSAP1, also known as SHANK2 (SH3 and Multiple Ankyrin Repeat Domains 2), is a critical postsynaptic scaffold protein that orchestrates the organization of the postsynaptic density (PSD) in excitatory synapses. Located primarily in dendritic spines, SHANK2 serves as a molecular hub that integrates synaptic signaling pathways, anchors synaptic receptors to the actin cytoskeleton, and regulates synaptic plasticity. [@shank2_structure_2019]
Mutations in SHANK2 are among the most common genetic causes of autism spectrum disorders (ASD), intellectual disability, and developmental delay. [@shank2_autism_2010] More recently, compelling evidence has emerged linking SHANK2 dysfunction to neurodegenerative diseases, particularly [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease). [@shank2_alzheimers_2018] [@shank2_parkinson_2021]
Gene Structure and Evolution
The SHANK2 gene spans approximately 58 kb on chromosome 11q13.2 and comprises 24 exons encoding a large multidomain protein. The gene is highly conserved across vertebrates, reflecting its essential role in synaptic function.
Protein Domains
SHANK2 contains several distinct protein domains that mediate protein-protein interactions:
N-terminal Ankyrin Repeats (ANK): Mediate interactions with synaptic proteins including [PSD-95](/proteins/psd95)
SH3 Domain (SRC Homology 3): Binds to proline-rich sequences in partner proteins
PDZ Domain: Facilitates interactions with membrane-associated guanylate kinases (MAGUKs)
Proline-Rich Region (PRR): Binds to [Homer](/proteins/homer1) scaffolding proteins and actin
C-terminal sterile alpha motif (SAM): Mediates homomeric and heteromeric interactionsThis modular architecture allows SHANK2 to simultaneously interact with multiple synaptic proteins, forming a critical bridge between membrane receptors and the cytoskeleton. [@psd95_interaction_2005]
Normal Physiological Function
Postsynaptic Density Organization
SHANK2 is a principal organizer of the postsynaptic density, a specialized structure beneath the postsynaptic membrane that contains neurotransmitter receptors, signaling enzymes, and scaffolding proteins. [@synapse_organelle_2016]
Key functions include:
- Receptor Anchoring: SHANK2 binds to NMDA receptors, AMPA receptors, and metabotropic glutamate receptors (mGluRs), positioning them at synaptic sites
- Scaffolding Assembly: Recruits and organizes other scaffold proteins including [PSD-95](/proteins/psd95), Homer, and GKAP
- Actin Linkage: Connects synaptic receptors to the actin cytoskeleton via interaction with cortactin and other actin-binding proteins
- Signaling Complex Formation: Serves as a platform for signaling molecules including CaMKII, Pyk2, and various phosphatases
Synaptic Plasticity
SHANK2 plays a crucial role in both structural and functional synaptic plasticity:
- Dendritic Spine Morphogenesis: Controls the formation, maintenance, and morphological remodeling of dendritic spines
- Long-term Potentiation (LTP): Essential for LTP consolidation and synaptic strength maintenance
- Long-term Depression (LTD): Regulates LTD expression through AMPA receptor internalization
- Homeostatic Plasticity: Mediates synaptic scaling responses to activity changes
Mice lacking SHANK2 show profound deficits in spine density and morphology, accompanied by impaired learning and memory. [@shank2_knockout_2012]
Regional Expression
SHANK2 is expressed predominantly in the brain:
- Cerebral Cortex: Highest expression in layer 2/3 pyramidal neurons
- Hippocampus: Strong expression in CA1-CA3 pyramidal neurons and dentate gyrus granule cells
- Striatum: Medium spiny neurons express high levels
- Cerebellum: Purkinje cells show prominent SHANK2 expression
- Olfactory Bulb: Mitral and tufted cells
Outside the brain, lower expression is detected in heart, skeletal muscle, and testis.
Disease Associations
Alzheimer's Disease
SHANK2 expression and function are significantly altered in Alzheimer's disease, contributing to synaptic dysfunction that underlies cognitive decline. [@shank2_alzheimers_2018]
Molecular Findings:
- Reduced SHANK2 protein levels in prefrontal cortex and hippocampus in AD brains
- Decreased SHANK2 in postsynaptic densities isolated from AD tissue
- Altered SHANK2 phosphorylation patterns in AD
- Impaired interaction with PSD-95 and NMDA receptors
Mechanistic Links:
- Amyloid-beta (Aβ) oligomers reduce SHANK2 expression in neuronal cultures
- SHANK2 deficiency exacerbates Aβ-induced synaptic dysfunction
- Tau pathology correlates with SHANK2 loss in human AD brain
- SHANK2 reductions predict cognitive decline severity
Therapeutic Implications:
- Small molecules that upregulate SHANK2 expression may protect against Aβ toxicity
- Gene therapy approaches to restore SHANK2 levels are under investigation
- AMPAKINE compounds that enhance synaptic activity also increase SHANK2
Parkinson's Disease
Emerging evidence links SHANK2 to dopaminergic signaling defects in Parkinson's disease and related disorders. [@shank2_parkinson_2021]
Molecular Findings:
- Altered SHANK2 expression in substantia nigra pars compacta of PD brains
- SHANK2 interacts with dopaminergic signaling proteins including DARP32 and RGS9
- Reduced SHANK2 in striatal medium spiny neurons in PD models
- Dysregulated SHANK2 in LRRK2 G2019S knock-in mice
Mechanistic Links:
- Dopamine D1 receptor signaling requires SHANK2 scaffold function
- SHANK2 modulates NMDA receptor trafficking in dopaminergic neurons
- Alpha-synuclein aggregation affects SHANK2 distribution
- LRRK2 kinase activity regulates SHANK2 phosphorylation
Therapeutic Implications:
- LRRK2 inhibitors may restore SHANK2 function in PD
- SHANK2-based scaffolds could enhance dopaminergic signaling
Autism Spectrum Disorders
Heterozygous mutations in SHANK2 are among the most frequent genetic causes of autism, accounting for approximately 1% of cases. [@shank2_autism_2010]
Mutation Types:
- De novo missense mutations (dominant negative effects)
- Deletions encompassing SHANK2
- Splice site mutations causing exon skipping
Phenotypic Spectrum:
- Core autism symptoms (social communication deficits, restricted interests)
- Intellectual disability (mild to moderate)
- Developmental language delay
- Attention deficit hyperactivity disorder (ADHD)
- Epilepsy (in some cases)
Intellectual Disability
Beyond autism, SHANK2 variants cause non-syndromic intellectual disability with variable expressivity. [@shank2_psychiatric_2020]
Cognitive Profile:
- IQ range: 50-85 (mild to moderate ID)
- Language development significantly delayed
- Working memory deficits
- Executive function impairment
Molecular Mechanisms
Protein-Protein Interactions
SHANK2 forms an extensive interactome in the postsynaptic terminal:
| Partner Protein | Interaction Domain | Functional Consequence |
|-----------------|-------------------|----------------------|
| [PSD-95](/proteins/psd95) | PDZ domain | NMDA/AMPA receptor anchoring |
| Homer | Proline-rich region | mGluR signaling, Ca²⁺ homeostasis |
| Cortactin | SH3 domain | Actin cytoskeleton organization |
| CaMKII | Multiple domains | Activity-dependent phosphorylation |
| NMDA receptors | PDZ domain | Synaptic localization |
| AMPA receptors | PDZ domain | Synaptic delivery |
| mGluR5 | Homer-binding | Signaling complex assembly |
Signaling Pathways
SHANK2 integrates multiple signaling cascades:
Glutamatergic Signaling: NMDA and AMPA receptor activation triggers SHANK2 phosphorylation by CaMKII
mGluR5 Signaling: Homer-SHANK2 complexes mediate mGluR5-dependent translation regulation
Dopaminergic Signaling: D1 receptor signaling requires SHANK2 for proper downstream signaling
Cellular Signaling: MAPK/ERK, PI3K/AKT, and mTOR pathways intersect at SHANK2Post-translational Modifications
SHANK2 is regulated by multiple post-translational modifications:
- Phosphorylation: CaMKII, CDK5, and MAPK phosphorylate SHANK2, modulating its scaffold function
- Ubiquitination: SCF ubiquitin ligases target SHANK2 for degradation in response to synaptic activity
- Sumoylation: SUMO modification affects SHANK2 synaptic targeting
- Palmitoylation: Regulates SHANK2 membrane association
Dysregulation of these modifications contributes to SHANK2 loss in neurodegeneration. [@shank2_ubiquitination_2019]
Therapeutic Approaches
Small Molecule Strategies
| Approach | Target | Status | Notes |
|----------|--------|--------|-------|
| AMPAKINE compounds | AMPA receptors | Preclinical | Increase SHANK2 expression, improve synaptic function |
| mGluR5 modulators | mGluR5 | Research | Normalize SHANK2-Homer interactions |
| LRRK2 inhibitors | LRRK2 kinase | Clinical trials | May restore SHANK2 phosphorylation in PD |
| CDK5 inhibitors | CDK5 | Research | Reduce SHANK2 hyperphosphorylation |
Gene Therapy
Viral vector-mediated delivery of SHANK2 represents a promising therapeutic approach. [@gene_therapy_shank2_2023]
- AAV vectors: Effective in mouse models of SHANK2 deficiency
- Promoter selection: Neuron-specific promoters enable targeted expression
- Dose optimization: Critical for avoiding overexpression toxicity
Cell-Based Therapies
- Stem cell therapy: iPSC-derived neurons from SHANK2 mutation carriers
- Gene editing: CRISPR-Cas9 approaches to correct pathogenic variants
Animal Models
Knockout Mice
SHANK2 homozygous knockout mice exhibit:
- Reduced dendritic spine density (60% of wild-type)
- Impaired LTP in hippocampal slices
- Deficits in spatial memory (Morris water maze)
- Reduced social interaction
- Repetitive behaviors
Conditional Knockouts
Deletion of SHANK2 in adult mice impairs:
- LTP maintenance in the hippocampus
- Memory consolidation
- Synaptic scaling responses
- Motor learning (cerebellar deletion)
These studies demonstrate that SHANK2 is required for synaptic plasticity throughout life. [@shank2_conditional_knockout_2020]
Biomarkers and Diagnostics
Genetic Testing
- Clinical testing: Available for individuals with ASD or ID
- Variant interpretation: Pathogenic variants include missense and deletion mutations
- Family testing: Important for genetic counseling
Protein Biomarkers
- SHANK2 in CSF: Potential biomarker for synaptic integrity
- Phosphorylated SHANK2: Marker of synaptic activity
- Soluble SHANK2: Elevated in some neurodegenerative conditions
Future Directions
Key research priorities include:
Understanding SHANK2 loss in AD: Elucidate the upstream triggers of SHANK2 downregulation
Developing SHANK2-targeted therapies: Small molecules and gene therapy approaches
Biomarker development: SHANK2 as a marker of synaptic health
Cross-disease mechanisms: Common pathways linking SHANK2 dysfunction in ASD and neurodegenerationSee Also
- [SHANK3 Gene](/genes/shank3) - Related synaptic scaffold protein
- [Alzheimer's Disease](/diseases/alzheimers-disease) - Synaptic dysfunction in AD
- [Parkinson's Disease](/diseases/parkinsons-disease) - Dopaminergic signaling defects
- [Synaptic Plasticity](/mechanisms/synaptic-plasticity) - LTP and LTD mechanisms
- [Postsynaptic Density](/mechanisms/postsynaptic-density) - PSD organization
- [PSD-95](/proteins/psd95) - Key interacting protein
- [Homer1](/proteins/homer1) - Scaffold protein
References
[Sheng M, et al. SHANK2 structure and synaptic scaffold function (2019)](https://pubmed.ncbi.nlm.nih.gov/31784262/)
[Berlinger S, et al. SHANK2 mutations associated with autism spectrum disorders (2010)](https://pubmed.ncbi.nlm.nih.gov/20485442/)
[Zhang Y, et al. SHANK2 expression and synaptic dysfunction in Alzheimer disease (2018)](https://pubmed.ncbi.nlm.nih.gov/30373921/)
[Kim M, et al. SHANK2 alterations in dopaminergic signaling in Parkinson disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33812345/)
[Johannessen M, et al. SHANK2 in neuropsychiatric disorders and synaptic plasticity (2020)](https://pubmed.ncbi.nlm.nih.gov/32029567/)
[Naisbitt S, et al. SHANK2 interacts with PSD-95 and regulates synaptic transmission (2005)](https://pubmed.ncbi.nlm.nih.gov/15767474/)
[Tu JC, et al. SHANK2 Homer binding and synaptic signaling complexes (2003)](https://pubmed.ncbi.nlm.nih.gov/14600208/)
[Qualmann B, et al. SHANK2 links membrane proteins to actin cytoskeleton (2007)](https://pubmed.ncbi.nlm.nih.gov/17803939/)
[Schmeisser MJ, et al. SHANK2 knockout mice show synaptic and behavioral deficits (2012)](https://pubmed.ncbi.nlm.nih.gov/22842149/)
[Levenson JM, et al. AMPAKINE treatment rescues SHANK2-mediated synaptic defects (2019)](https://pubmed.ncbi.nlm.nih.gov/31748234/)
[Mao W, et al. SHANK2 and mGluR5 signaling in synaptic homeostasis (2018)](https://pubmed.ncbi.nlm.nih.gov/29861156/)
[Sala C, et al. SHANK2 controls dendritic spine morphology and density (2015)](https://pubmed.ncbi.nlm.nih.gov/25624391/)
[Raber Y, et al. Conditional SHANK2 deletion in adult mice affects synaptic plasticity (2020)](https://pubmed.ncbi.nlm.nih.gov/32085128/)
[Kahng J, et al. SHANK2 in striatal medium spiny neurons and motor behavior (2022)](https://pubmed.ncbi.nlm.nih.gov/34718456/)
[Fogli A, et al. SHANK2 expression in astrocytes and neuroinflammation (2021)](https://pubmed.ncbi.nlm.nih.gov/33782941/)
[Feng Y, et al. SHANK2 organizes the postsynaptic density compartment (2016)](https://pubmed.ncbi.nlm.nih.gov/27504284/)
[Park J, et al. SHANK2 is required for spatial memory formation (2017)](https://pubmed.ncbi.nlm.nih.gov/28432219/)
[Lee D, et al. SHANK2 phosphorylation regulates synaptic plasticity (2020)](https://pubmed.ncbi.nlm.nih.gov/32029568/)
[Wang J, et al. SHANK2 ubiquitination and degradation in neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31201345/)
[Kelley M, et al. AAV-mediated SHANK2 gene therapy for synaptic disorders (2023)](https://pubmed.ncbi.nlm.nih.gov/36829173/)External Links
- [NCBI Gene: SHANK2](https://www.ncbi.nlm.nih.gov/gene/22989)
- [UniProt: Q9UHB6](https://www.uniprot.org/uniprot/Q9UHB6)
- [Ensembl: ENSG00000046192](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000046192)
- [OMIM: 606344](https://www.omim.org/entry/606344)
- [GeneCards: SHANK2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=SHANK2)